Markets News

Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.

BioNTech Slumps 6.6% as Colorectal Cancer Vaccine Trial Halted
Markets Daniel Marsh

BioNTech Slumps 6.6% as Colorectal Cancer Vaccine Trial Halted

BioNTech shares dropped 6.6% after the company ended a Phase 2 trial of its colorectal cancer vaccine. The decision follows a data safety board recommendation and erases about $1.8 billion in market value.

RHHBY
Moderna Drops 3.4% on $2.6B Convertible Offering Amid Cancer Vaccine Rally
Markets Daniel Marsh

Moderna Drops 3.4% on $2.6B Convertible Offering Amid Cancer Vaccine Rally

Moderna shares slid 3.4% to $137.86 after pricing a $2.6B zero-coupon convertible notes offering, sparking dilution worries and cooling the recent cancer-vaccine rally.

MRNA
Roivant Dips 2.7% Despite FDA Nod for LISRAYA; JPMorgan Sees $2B Peak Sales
Markets Daniel Marsh

Roivant Dips 2.7% Despite FDA Nod for LISRAYA; JPMorgan Sees $2B Peak Sales

Roivant shares slipped 2.7% to $36.58 despite FDA approval of LISRAYA, the first oral treatment for dermatomyositis. JPMorgan sees peak U.S. sales exceeding $2 billion.

ROIV
Kazia Therapeutics Slides 7.3% on $40M Equity Offering After Clinical Rally
Markets Daniel Marsh

Kazia Therapeutics Slides 7.3% on $40M Equity Offering After Clinical Rally

Kazia Therapeutics shares dropped 7.3% after pricing a $40 million equity offering, capitalizing on a recent clinical data surge but diluting existing shareholders.

BioLineRx Plunges 20% on Dilutive $3.75M Offering
Markets Daniel Marsh

BioLineRx Plunges 20% on Dilutive $3.75M Offering

BioLineRx shares dropped 20% after a $3.75M offering priced at $2.78 per ADS, with warrants that could significantly increase dilution.

Quoin Rockets 42% on QRX003 Data, Unveils $50M Funding Plan
Markets Daniel Marsh

Quoin Rockets 42% on QRX003 Data, Unveils $50M Funding Plan

Quoin shares jumped 41.8% after QRX003 met its primary endpoint in an interim analysis. The company also announced a $50 million fundraising.

Marvell Stock Slides 6.9% as Google AI Revenue Shift Delays Boost to 2029
Markets Daniel Marsh

Marvell Stock Slides 6.9% as Google AI Revenue Shift Delays Boost to 2029

Marvell shares dropped 6.9% premarket after Google's AI revenue timeline pushed significant gains to fiscal 2029, despite record Q2 revenue.

MRVL GOOGL AVGO
PayPal Plunges 15% as $53B Acquisition Talks Collapse
Markets Daniel Marsh

PayPal Plunges 15% as $53B Acquisition Talks Collapse

PayPal shares tumbled 15.4% after dropping a $53 billion acquisition attempt, wiping out $8.1 billion in market value and raising growth concerns.

PYPL
Founder Group Slumps 23% Premarket on Second Reverse Split
Markets Daniel Marsh

Founder Group Slumps 23% Premarket on Second Reverse Split

Founder Group shares fell 22.7% in premarket trading after the company revealed a second 100-for-1 reverse stock split, its second in seven months, set to take effect September 1.

FGL
E-Power Soars 23% on Record $51.1M Anode Contract
Markets Daniel Marsh

E-Power Soars 23% on Record $51.1M Anode Contract

E-Power shares surged 23% premarket after securing a $51.1 million anode-line contract, which exceeds its 2025 revenue. The project adds 21,000 tons of annual capacity.

Propanc Biopharma Plunges 19% Premarket After 108% Surge on PRP Data
Markets Daniel Marsh

Propanc Biopharma Plunges 19% Premarket After 108% Surge on PRP Data

Propanc Biopharma (PPCB) shares dropped 19.3% premarket to $1.80 after a 108% surge on PRP data. Despite strong animal results, revenue and cash concerns persist.

PPCB
Solstice Surges 17% After Scrapping $14.5B Merger, Unveiling $500M Buyback
Markets Daniel Marsh

Solstice Surges 17% After Scrapping $14.5B Merger, Unveiling $500M Buyback

Solstice shares surged 17.2% in premarket trading after the company terminated its $14.5 billion merger with Element Solutions and announced a $500 million buyback.

SOLS ESI